1、White PaperMind over matter:The growing momentum of CNS innovation How innovators are beating the odds in a high-stakes therapeutic areaMARKUS GORES,Vice President,EMEA Thought Leadership,IQVIASTEFAN LUTZMAYER,Senior Consultant,EMEA Thought Leadership,IQVIATable of contentsIntroduction 1Unmet need i

2、s accelerating 1Pushing the frontiers of CNS innovation 3Neuroinflammation3The gut-brain axis 4Psychedelics 5Digital health 6Innovation momentum and the competitive landscape in CNS 9Deep dive:CNS indication highlights 13I.Alzheimersdisease13II.Mental health 15CNS market outlook 19How to succeed as

3、a CNS innovator 20References 22About the authors 26 |1IntroductionThe global burden of illness related to Central Nervous System(CNS)disorders keeps rising unabatedly,with hugeeconomicimplications.By2030,theglobaleconomic cost of mental health conditions alone is projected to reach$6 trillion,1 for

4、example,while the economic burden of Alzheimers and related dementias is estimated to rise to$4.7 trillion.2These extraordinary numbers reinforce the urgent need for novel therapeutic interventions to treat CNS disorders,however,the title of our previous publicationfrom2023,“Twostepsforward,onestep

5、back:The long road to success in CNS”3 still rings true today,as innovators continue to navigate the high-stakes roller coaster of developing and commercialising new CNS therapies.Notwithstanding well publicised setbacks,numerous examplesillustratethesignificantprogressmadeinexpanding CNS therapeuti

6、c options to give hope to patients,their families and caregivers.For example,the approval of Cobenfy represents thefirstnewapproachfortreatingschizophreniainover30years,bytargetingcholinergicreceptorsasopposed to dopamine receptors;NMDA-targeting Spravato(esketamine)for treatment-resistant depressio